Ribomed Biotechnologies, Inc.

Ribomed Biotechnologies is a translational genomics company developing rapid, specific, and robust tests for the early detection and characterization of diseases and their causative agents and the screening of drugs for treatment. Ribomed (formerly Designer Genes, Inc.), formed in April 1999 by Dr. Michelle M. Hanna, has developed a proprietary platform signal generation method (Abscription™) and reagents for the rapid, isothermal detection and characterization of RNA, DNA, and protein targets. The Company has received over $5 million in government grants and contracts to develop this technology for the detection of cancer, infectious disease, and biological pathogens.  Ribomed is positioned to launch diagnostic products into the molecular diagnostic market and the biodefense market.

Ribomed is dedicated to improving life through early disease detection, non-invasive monitoring, and patient-specific therapies.

For current Jobs Click here